tirzepatide death SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I Tirzepatide linked to lower risk
Pay in 4 interest-free payments of $5.87 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11


























![Smoking a Cigarette on the Shinkansen at 176mph [UNCUT]](https://i.ytimg.com/vi/zmHWYcPWZJs/maxresdefault.jpg)


